To address the ground truth of the subtype of each patient tumor correlating with multi-dimensional genomic data such as MGMT methylation status9,31 and IDH1/2 mutations4, and more recently, TERT and ATRX mutations32, will require larger resources and scale of study. This evidence concerns the gene IDH1 and neoplasm.